← Xizang Haisco Pharmaceutical overview

Xizang Haisco Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Xizang Haisco Pharmaceutical Group Co Ltd (002653.CS)

Q3 2026
▲3▼1

Haisco Soars on Profit Surge and New Licensing Deals

  • Profit Surge and Strong Financials Haisco's first-half net profit jumped 513–575% on innovative drug sales and licensing upfronts, with revenue of 3.1 billion yuan and net profit of 851 million yuan, boosting investor confidence.

    This massive earnings growth was a primary driver of the stock's positive performance.

  • Major Licensing Deals Validate Platform New deals including a $75.89 million upfront Sentivera agreement potentially worth $1.5 billion and AbbVie's HSK51155 partnership validated Haisco's drug discovery platform and future revenue potential.

    These deals provided significant external validation and upfront cash, fueling optimism.

  • Pipeline Progress and Dividend Confidence HSK60002 approval and partner AirNexis' positive Phase 2b COPD trial advanced the pipeline, while a planned 600 million yuan dividend and subsidiary funding signaled cash confidence.

    Pipeline milestones and capital returns reinforced growth prospects and financial health.

  • Tax Compliance Issue Weighs Slightly A tax bureau flagged a subsidiary for receiving 1.26 million yuan in fake VAT invoices, creating modest compliance and penalty risk that slightly weighed on shares.

    This was the main negative factor, though its impact was limited.

August 2026
▲3▼1

Haisco Soars on Profit Surge and New Licensing Deals

  • Profit Surge and Strong Financials Haisco's first-half net profit jumped 513–575% on innovative drug sales and licensing upfronts, with revenue of 3.1 billion yuan and net profit of 851 million yuan, boosting investor confidence.

    This massive earnings growth was a primary driver of the stock's positive performance.

  • Major Licensing Deals Validate Platform New deals including a $75.89 million upfront Sentivera agreement potentially worth $1.5 billion and AbbVie's HSK51155 partnership validated Haisco's drug discovery platform and future revenue potential.

    These deals provided significant external validation and upfront cash, fueling optimism.

  • Pipeline Progress and Dividend Confidence HSK60002 approval and partner AirNexis' positive Phase 2b COPD trial advanced the pipeline, while a planned 600 million yuan dividend and subsidiary funding signaled cash confidence.

    Pipeline milestones and capital returns reinforced growth prospects and financial health.

  • Tax Compliance Issue Weighs Slightly A tax bureau flagged a subsidiary for receiving 1.26 million yuan in fake VAT invoices, creating modest compliance and penalty risk that slightly weighed on shares.

    This was the main negative factor, though its impact was limited.

Latest
▲3▼1

Haisco's profit, pipeline wins and dividend offset tax-invoice hit

  • Tax bureau flags false invoices at Haisco subsidiary A tax bureau named a Haisco holding subsidiary among five drugmakers that received fake VAT invoices worth 1.26 million yuan from a now-deregistered vendor. The amount is small, but it raises compliance and possible penalty risk, a modest drag on the shares.

    It is the only clearly negative regulatory event in the period and a real counterweight to the good news.

  • Interim profit of 851 million yuan on 3.1 billion revenue Haisco's first-half 2026 report showed revenue of 3.096 billion yuan and net profit of 851 million yuan, with strong cash flow and a 17.68% return on equity. Solid earnings and a healthy balance sheet support the stock's value.

    The interim results are the core fundamental update that tells readers how the business is actually performing.

  • New drug approvals and partner trial success lift pipeline Haisco's HSK60002 tablet won Chinese clinical trial approval for inflammatory disease, and partner AirNexis said AN01 met its main goal in a China Phase 2b COPD study run by Haisco. Both validate the pipeline and raise hopes for future revenue.

    These are the period's main technology catalysts that can drive long-term growth expectations.

  • Dividend and subsidiary funding show cash confidence Haisco plans to pay 5.26 yuan per 10 shares, about 600 million yuan, and will lend up to 261 million yuan to its new biotech subsidiary for ADC and CAR-T research. Returning cash while funding growth signals confidence in its finances.

    The payout and internal funding show management's confidence and support shareholder returns, a positive capital signal.

▲4

Haisco's profit surge and new licensing deals drive gains

  • First-half profit forecast up over 500% Haisco expects first-half net profit to rise 513% to 575% year-on-year, driven by rapid innovative drug sales and upfront payments from out-licensing deals. This signals strong earnings momentum and boosts investor confidence in the stock.

    This is the core earnings catalyst that directly explains the stock's positive momentum.

  • New pain drug HSK51155 gets clinical trial approval Haisco's self-developed oral pain drug HSK51155 received clinical trial approval in China. It is part of a global partnership with AbbVie worth over $700 million, validating Haisco's research capabilities and adding a potential future revenue stream.

    This pipeline advancement supports long-term growth prospects and reinforces the value of Haisco's licensing strategy.

  • New autoimmune licensing deal with Sentivera Haisco licensed a preclinical autoimmune asset to US-based Sentivera for $75.89 million upfront (cash plus equity), up to $1.46 billion in milestones, and royalties. This brings immediate cash and validates Haisco's drug discovery platform.

    This is a fresh, material deal that directly adds near-term cash and potential long-term value.

  • Sentivera launch highlights China biotech out-licensing trend Sentivera, backed by Metsera investors, licensed Haisco's immunology asset, with total deal value potentially exceeding $1.5 billion. This NewCo model is gaining traction, boosting Haisco's reputation and future deal-making potential.

    It underscores the growing demand for Chinese biotech assets and Haisco's ability to secure favorable terms.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.